NFKB1 and inflammatory bowel disease: Its ability to concurrently activate cytoprotective Nrf2 signaling and suppress NF-κB-mediated inflammation underscores its pharmacological versatility, positioning Eng as an ideal candidate for addressing the multifactorial nature of IBD.